- Research article
- Open Access
- Open Peer Review
Use of iQPR-H2O for bone regeneration and its potential in the improvement of osteoporosis
© Lee et al; licensee BioMed Central Ltd. 2011
- Received: 31 December 2010
- Accepted: 8 October 2011
- Published: 8 October 2011
Current treatments for osteoporosis are associated with various side effects and do not prevent the age-related decrease in osteoblast number. The objective of this study was to evaluate the effects of iQPR-H2O on osteogenesis.
Mouse fibroblast NIH3T3 and pre-osteoblastic MC3T3-E1 cells were cultured in medium prepared with iQPR-H2O or unprocessed mineral water (control cells), and proliferation and differentiation were assessed by MTT and alkaline phosphatase assay, respectively. Mineral deposition by the cells was determined using Alizarin red S staining. A mouse model of osteoporosis, ovariectomized SAMP8 mice, was used to evaluate the effects of iQPR-H2O on osteogenesis in vivo. Mice were given either iQPR-H2O or unprocessed mineral water (control group) for four months after which bone mass density (BMD) measurements were made using a bone densitometer and hematoxylin and eosin staining of bone samples.
NIH3T3 cells grown in medium prepared with iQPR-H2O exhibited significantly greater proliferation. NIH3T3 and MC3T3-E1 cells demonstrated a significant increase in alkaline phosphatase levels in the iQPR-H2O group. MC3T3-E1 cells showed mineralization at day 28. mRNA expression levels of both osteopontin and runt-related transcription factor 2 in MC3T3-E1 cells were higher in the iQPR-H2O group compared with the control group. After four months, significantly greater bone regeneration was evident in ovariectomized SAMP8 mice administered iQPR-H2O as compared with control group.
iQPR-H2O may reduce the symptoms of osteoporosis by improving osteogenesis.
- Quantum Persistent Reflection
- mouse fibroblasts
- senescence-accelerated mice
- bone mass density
Osteoporosis is a disease characterized by abnormal bone metabolism caused by an imbalance in bone remodeling, which reduces bone density and increases the incidence of fractures [1, 2]. Current treatments for osteoporosis inhibit bone density loss through pharmaceutical and non-pharmaceutical methods [3, 4]. Non-pharmaceutical treatments include calcium and vitamin D supplementation [5–8] and regular weight-bearing exercise . Pharmaceutical treatments include bisphosphonates, hormones, parathyroid hormones, and calcitonin, which inhibit resorption or stimulate bone generation . However, adverse effects, including bone necrosis, hyperparathyroidism, vein thrombosis, hot flashes, and foot cramps, have been reported as a consequence of pharmaceutical treatments . In addition, current treatments do not address the fundamental cause of osteoporosis, namely, bone loss due to an age-related reduction in the number of osteoblasts .
Infinitesimal Quantum persistent reflection (QPR™) element water(iQPR-H2O) is prepared by a steady device of matter energy, which is a patented technology developed by Mr. Lam Gow Lin (New Technology Number M 273565; United States Patent Application 20060099120; http://www.freepatentsonline.com/y2006/0099120.html) based on the theory of controlling "time parameters, quantum movements, and specific spaces" . Specifically, in steady device of matter energy, a reaction column is programmed such that invisible light can cause interference, superposition, reflection, and dispersion for a set amount of time and in a fixed space. Upon treatment, bonds of molecules are broken, thereby producing elements and small molecules after which they are rearranged, increasing the energy state of matter. This treatment can be applied to drinking water, cosmetics, wine, and medical treatments, thereby increasing their energy states.
The present study tested the hypothesis that iQPR-H2O would promote bone deposition in osteoporosis. Therefore, the effects of iQPR-H2O on mouse fibroblast (NIH3T3) and osteoblastic (MC3T3-E1) cell lines were examined. NIH3T3 cells have the capacity to differentiate into osteoblasts [12, 14, 15]. Specifically, cell proliferation, differentiation, and mineral deposition in response to iQPR-H2O were assessed. In addition, the effects of iQPR-H2O on bone mineral density (BMD) using a mouse model of osteoporosis, ovariectomized SAMP8 (OVX-SAMP8) mice [16, 17], was analyzed.
Characterization of iQPR-H2O
Elements in iQPR-H2O: a comparison with unprocessed mineral water.
Unprocessed mineral water
In vitro studies
Proliferation and viability
NIH3T3 fibroblast (ATCC CRL-1658) and MC3T3-E1 pre-osteoblastic (ATCC CRL-2593) cells (provided by the cell line center, China Medical University, Taichung, Taiwan) were cultured in 96-well plates (2 × 103 cells/well) in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum and prepared with sterilized iQPR-H2O or unprocessed mineral water (control medium) for 0, 1, 3, 5, 7, or 9 days. Cell proliferation at the end of each time point was determined using a Cell Growth Determination Kit (Sigma-Aldrich, St. Louis, MO) following manufacturer's instructions.
NIH3T3 and MC3T3-E1 cells were cultured in 6-well plates (1 × 105 cells/well) in iQPR-H2O-containing or control media for 0, 1, 3, 5, or 7 days. Differentiation was determined at the end of each time point by assessing alkaline phosphatase (ALP) levels as previously described . Exposure of cells to iQPR-H2O was extended to 14 and 28 days after which ALP expression was measured.
mRNA Expression of osteopontin and runt-related transcription factor 2
mRNA expression levels of osteopontin (OPN) and runt-related transcription factor 2 (RUNX2) were assessed in MC3T3-E1 cells after 28 days of culture in iQPR-H2O-containing or control media. Total RNA was extracted from cells using TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA). Gene expression levels were measured by reverse-transcription polymerase chain reaction (PCR). The following PCR primers were used:
OPN forward primer, 5'-ATGAGATTGGCAGTGATT-3';
OPN reverse primer, 5'-GTTGACCTCAGAAGATGA-3';
RUNX2 forward primer, 5'-ACTTTCTCCAGGAAGACTGC-3';
RUNX2 reverse primer, 5'-GCTGTTGTTGCTGTTGCTGT-3';
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) forward primer 5', GCTCTCCAGAACATCATCCCTGCC-3';
GAPDH reverse primer, 5'-CGTTGTCATACCAGGAAATGAGCTT-3'.
PCR products were separated by electrophoresis on 1% agarose gels (Agarose I; AMRESCO, Solon, OH, USA) and visualized using ethidium bromide staining.
MC3T3-E1 cells were cultured in 2-cm diameter plates (1 × 104 cells/plate) in iQPR-H2O-containing or control media for 28 days. Cell mineralization was determined by staining with Alizarin red S (Sigma-Aldrich) as previously described .
In vivo studies
Animals and preparation
All animal experiments were approved by the Laboratory Animal Research Committee of Taipei Medical University. Female SAMP8 mice (Providence University, Taichung, Taiwan) were maintained in a clean environment with a temperature between 22 to 24°C and 50% humidity and received food (BioLASCO Taiwan Co., Ltd., Taipei, Taiwan) and regular drinking water ad libitum. Mice were ovariectomized (OVX) at four months of age to induce osteoporosis following the protocol described by Lo et al. . Two weeks after the surgery (T = 0), OVX-SAMP8 mice received iQPR-H2O (experimental group; n = 6) or unprocessed mineral water (control group; n = 6) for four months. BMD was determined each month. After four months, the mice were sacrificed, and bone samples were obtained for further analysis.
Bone mass density analysis
Baseline BMD was measured two weeks after the SAMP8 mice were ovariectomized (T = 0) and at one-month intervals for four months using the XR-36 bone densitometer (Norland Products Inc., Cranbury, NJ). Data were acquired using scanner software version 2.0.0 (Norland Products Inc., Cranbury, NJ) and analyzed using host software version 2.5.3 (Norland Products Inc., Cranbury, NJ). Changes in spine, knee, and femur BMD (g/cm2) were compared with the baseline BMD values.
Hematoxylin and eosin (H&E) staining
Subsets of six mice were sacrificed two weeks after ovariectomy (T = 0) and one and four months later. After the mice were sacrificed, spine, femur, and tibial bone (knee) samples were removed and fixed in 10% formaldehyde. Samples were softened in decalcification fluid, embedded in paraffin, and sectioned (10 μm thick) for H&E staining. Three sections, which represent three locations in bone, were examined using a microscopic digital camera (Pixera Penguin 150CL Cooled CCD, San Jose, CA), and the area of interest was measured and analyzed.
Normally distributed continuous variables between the control and iQPR-H2O groups were compared using independent two-sample t-test. Data are presented as means ± standard deviation (SD). All statistical assessments were two-sided and evaluated at the 0.05 level of significant difference. Statistical analyses were performed using SPSS 15.0 statistics software (SPSS Inc, Chicago, IL).
Effect of iQPR-H2O on NIH3T3 cell proliferation
Effect of iQPR-H2O on NIH3T3 and MC3T3-E1 cell differentiation
Effect of iQPR-H2O on MC3T3-E1 cell mineralization
Effect of iQPR-H2O on BMD in OVX-SAMP8 mice
Effect of iQPR-H2O on bone density in OVX-SAMP8 mice as determined by H&E analysis
The effects of iQPR-H2O on cell proliferation, differentiation and mineral deposition as well as bone formation were analyzed in this study under in vitro condition using NIH3T3 fibroblast and MC3T3-E1 osteoblastic cell lines, and under in vivo condition using mouse model of osteoporosis as described previously . NIH3T3 cells treated with iQPR-H2O displayed an increased ability to proliferate. Both NIH3T3 and MC3T3-E1 cells in iQPR-H2O-containing medium showed higher levels of differentiation compared with control cells. In vivo studies revealed that iQPR-H2O increased BMD in OVX-SAMP8 mice, indicating that under long-term induction, osteoblasts may be capable of differentiation and improving the symptoms of osteoporosis.
MC3T3-E1 cells showed a sign of differentiation i.e. significantly higher ALP level than control, 7 days after culture in iQPR-H2O-containing medium. Further, expression of both OPN and RUNX2 mRNA was higher in the iQPR-H2O group compared with the control group after 28 days of culture. This observation is similar to that from a previous report showing that ALP levels were significantly higher 7 days after MC3T3-E1 cells were stimulated with ascorbic acid and b-glycerophosphate . OPN has been reported to modulate both mineralization and bone resorption, and RUNX2 is one of the major regulators of OPN in osteoblastic cells . Increased expression of both OPN and RUNX2 28 days after the culture suggests that iQPR-H2O may have promoted differentiation and mineralization of MC3T3-E1 cells. In contrast to MC3T3-E1 cells, increased differentiation of NIH3T3 cells was only observed in cells cultured for 14 to 28 days in the presence of iQPR-H2O. There were no statistically significant differences in ALP expression between the iQPR-H2O-treated and control cells at earlier time points (ie, within 7 days). This may be explained by the cells being in a proliferative state, which has been reported to delay differentiation , within the first 7 days of culture.
Previous studies of bone remodeling have reported that there are five stages to this process: activation, resorption, reversal, formation, and quiescence. Progression from activation to resorption was found to take place over two weeks, whereas three to four months transpired between reversal and formation, and finally quiescence [23, 24]. In the present study, OVX-SAMP8 mice exhibited increased bone density after four months treatment with iQPR-H2O. This time frame is comparable to that over which bone remodeling takes place. H&E findings corroborated the BMD analysis findings.
Bone densities in iQPR-H2O-treated OVX-SAMP8 mice declined between zero and two months and then rebounded during the third month. This presumably reflects osteoclast resorption of old bone caused by secretion of ALP, collagenase, lysosomal enzymes, and proteases, followed by stimulation and recruitment of osteoblasts into the site of osteoporosis. The formation period is a slow phase, which takes approximately 35 to 40 days, which coincides with the BMD changes observed over the four-month period in the present study.
Of note, we found that left knee BMD, as determined by bone densitometry was not significantly increased in mice treated with iQPR-H2O compared with control. This is a very puzzling finding for which we do not have an explanation. Indeed, the lack of a significant change in the left knee BMD as determined by bone densitometry is inconsistent with the findings for all other measures of BMD and bone density. We can only assume that the observed BMD findings are a statistical anomaly.
iQPR-H2O has approximately 60% less calcium than unprocessed mineral water. It is well known that inadequate intake of vitamin D and calcium can lead to reduced calcium absorption, a higher rate of bone remodeling, and increased bone loss. Although we have not assessed calcium homeostasis in mice treated with iQPR-H2O, we do not believe that a 60% reduction in the calcium content of drinking water would significantly alter calcium homeostasis given that the vast majority of calcium is obtained through the diet.
The mechanism by which iQPR-H2O influences bone remodeling remains to be investigated. iQPR-H2O may have increased the uptake of bone-associated elements from the diet in the experimental animals. As compared with unprocessed mineral water, iQPR-H2O had relatively high concentrations of magnesium, zinc, and silicon. Although the mechanism associating with the change in the level of elements is still unknown, this outcome is reproducible.
The importance of magnesium, zinc, and silicon and their deficiencies on BMD has been demonstrated in numerous studies. For example, magnesium deficiency has been associated with hypertension, cardiac arrhythmias, myocardial infarction, hypokalemia and hypocalcemia . Epidemiological studies revealed that BMD of the spine was significantly correlated with magnesium intake in premenopausal women . A cross-sectional study reported a significant correlation between magnesium intake and hip BMD men aged 69-97 years .
Several studies have assessed the effect of magnesium therapy for osteoporosis with varied results. Specifically, a prospective study in which postmenopausal osteoporotic women were given 250 mg of magnesium per day reported a significant 2.8% increase in the bone density of the distal radius at one year; however, no significant differences were shown at two years, which may be due to the small number (n = 10) of patients completing the study . A retrospective study in which postmenopausal women received 200 mg of magnesium per day resulted in a small, non significant 1.6% rise in lumbar spine bone density, and no differences were reported in the femur . In another small uncontrolled trial, a significant increase in the bone density of the proximal femur and lumbar spine was found in patients with gluten-sensitive enteropathy who received 504-576 mg of magnesium per day for two years .
Discrepant effects of zinc on bone progenitor cells have been reported. For example, in bone marrow cells, the highest ALP activity was observed when they were cultured on the ceramics with 1.26 wt% zinc; the ceramics released zinc ions at concentrations ranging from 2.2 to 7.2 μg/mL into the culture medium . Zinc ions were incorporated into mineralized areas produced by bone marrow cells. In addition, bone marrow cells cultured in medium supplemented with 100 μM ZnCl2 had significantly increased the ALP activity . However, Popp et al.  reported no differences in rat bone marrow stromal cell number, ALP activity, total protein content, collagen synthesis, or matrix mineralization in response to zinc supplementation.
Associations between silicon intake and BMD have also been seen. The most readily bioavailable source of silicon in the diet includes drinking water as well as other fluids, accounting for ≥ 20% of the total dietary intake . Beneficial effects on bone and other connective tissues have been observed upon silicon supplementation. For example, dietary silicon intake is associated with higher bone mineral density (BMD) . In osteoporotic subjects, silicon supplementation with monomethyl trisilanol resulted in increased bone volume and increases in femoral and lumbar spine BMD .
One limitation of this study is that increasing the energy state of water after processing with steady device of matter energy was not measured quantitatively, and that the mechanism associating with the change in the level of elements after the process was unknown. A further limitation is that ALP activity levels were found to increase with time in control MC3T3-E1 cells. This finding is puzzling and suggests that the cells were undergoing spontaneous differentiation under the culture conditions without extracellular stimulation.
This is the first study to analyze the effect of iQPR-H2O on bone remodeling in animals. iQPR-H2O ameliorated symptoms of osteoporosis and improved bone matrix. Further studies are needed to analyze the mechanism by which iQPR-H2O exerts its effects on osteogenesis and to determine if the beneficial effects of iQPR-H2O on osteogenesis are mediated through increased intake of magnesium, zinc, or silicon. The effects of iQPR-H2O on endogenous stem/progenitor cells in bone marrow will also be analyzed. iQPR-H2O may ultimately prove to be a useful treatment for osteoporosis.
The authors gratefully acknowledge Mr. Lam Gow Lin for providing the iQPR-H2O and quality control. We would also like to thank Milligrams Instruments Co., Ltd. for performing the BMD measurements.
- Riggs BL: Overview of osteoporosis. West J Med. 1991, 154: 63-77.PubMedPubMed CentralGoogle Scholar
- Rosen CJ, Bouxsein ML: Mechanisms of disease: is osteoporosis the obesity of bone?. Nat Clin Pract Rheumatol. 2006, 2: 35-43. 10.1038/ncprheum0070.View ArticlePubMedGoogle Scholar
- Delmas PD: Treatment of postmenopausal osteoporosis. Lancet. 2002, 359: 2018-2026. 10.1016/S0140-6736(02)08827-X.View ArticlePubMedGoogle Scholar
- Bonura F: Prevention, screening, and management of osteoporosis: an overview of the current strategies. Postgrad Med. 2009, 121: 5-17.View ArticlePubMedGoogle Scholar
- Chapuy MC, Pamphile R, Paris E, Kempf C, Schlichting M, Arnaud S, Garnero P, Meunier PJ: Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int. 2002, 13: 257-264. 10.1007/s001980200023.View ArticlePubMedGoogle Scholar
- Trivedi DP, Doll R, Khaw KT: Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ. 2003, 326: 469-10.1136/bmj.326.7387.469.View ArticlePubMedPubMed CentralGoogle Scholar
- Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, Staehelin HB, Bazemore MG, Zee RY, Wong JB: Effect of Vitamin D on falls: a meta-analysis. JAMA. 2004, 291: 1999-2006. 10.1001/jama.291.16.1999.View ArticlePubMedGoogle Scholar
- Lips P: Vitamin D physiology. Prog Biophys Mol Biol. 2006, 92: 4-8. 10.1016/j.pbiomolbio.2006.02.016.View ArticlePubMedGoogle Scholar
- American College of Sports Medicine position stand. Osteoporosis and exercise. Med Sci Sports Exerc. 1995, 27: i-vii.Google Scholar
- Keen R: Osteoporosis: strategies for prevention and management. Best Pract Res Clin Rheumatol. 2007, 21: 109-122. 10.1016/j.berh.2006.10.004.View ArticlePubMedGoogle Scholar
- Rimes KA, Salkovskis PM, Shipman J: Psychological and behavioural effects of bone density screening for osteoporosis. Psychology & Health. 1999, 14: 585-608.View ArticleGoogle Scholar
- Lo WC, Chiou JF, Gelovani JG, Cheong ML, Lee CM, Liu HY, Wu CH, Wang MF, Lin CT, Deng WP: Transplantation of embryonic fibroblasts treated with platelet-rich plasma induces osteogenesis in SAMP8 mice monitored by molecular imaging. J Nucl Med. 2009, 50: 765-773. 10.2967/jnumed.108.057372.View ArticlePubMedGoogle Scholar
- Laage D, Hynes JT: A molecular jump mechanism of water reorientation. Science. 2006, 311: 832-835. 10.1126/science.1122154.View ArticlePubMedGoogle Scholar
- Shui C, Scutt AM: Mouse embryo-derived NIH3T3 fibroblasts adopt an osteoblast-like phenotype when treated with 1alpha,25-dihydroxyvitamin D(3) and dexamethasone in vitro. J Cell Physiol. 2002, 193: 164-172. 10.1002/jcp.10157.View ArticlePubMedGoogle Scholar
- Sun WB, Wang J, Lu C, Tang GX: Effects of secretive bone morphogenetic protein 2 induced by gene transfection on the biological changes of NIH3T3 cells. Chin Med J (Engl). 2005, 118: 1703-1709.Google Scholar
- Chen H, Yao XF, Emura S, Shoumura S: Morphological changes of skeletal muscle, tendon and periosteum in the senescence-accelerated mouse (SAMP6): a murine model for senile osteoporosis. Tissue Cell. 2006, 38: 325-335. 10.1016/j.tice.2006.08.001.View ArticlePubMedGoogle Scholar
- Chen CC, Liu MH, Wang MF: Effects of aging and dietary antler supplementation on the calcium-regulating hormones and bone status in ovariectomized SAMP8 mice. Chin J Physiol. 2007, 50: 308-314.PubMedGoogle Scholar
- Sierra RI, Specker BL, Jiménez F, Cruz C, Pedraza-Chaverrí J: Biochemical bone markers, bone mineral content, and bone mineral density in rats with experimental nephrotic syndrome. Ren Fail. 1997, 19: 409-424. 10.3109/08860229709047727.View ArticlePubMedGoogle Scholar
- Han L, Zhang XL, Li X, Tang GH: Hedgehog pathway is associated with the proliferation and differentiation of osteoblasts. Shanghai Kou Qiang Yi Xue. 2009, 18: 287-290. (in Chinese)PubMedGoogle Scholar
- Yazid MD, Ariffin SH, Senafi S, Razak MA, Wahab RM: Determination of the differentiation capacities of murines' primary mononucleated cells and MC3T3-E1 cells. Cancer Cell Int. 2010, 28;10: 42-View ArticleGoogle Scholar
- Shen Q, Christakos S: The vitamin D receptor, Runx2, and the Notch signaling pathway cooperate in the transcriptional regulation of osteopontin. J Biol Chem. 2005, 280: 40589-98. 10.1074/jbc.M504166200.View ArticlePubMedGoogle Scholar
- Chang WH, Chen LT, Sun JS, Fin FH: Effect of pulse-burst electromagnetic field stimulation on osteoblast cell activities. Bioelectromagnetics. 2004, 25: 457-465. 10.1002/bem.20016.View ArticlePubMedGoogle Scholar
- Mundy GR: Cellular and molecular regulation of bone turnover. Bone. 1999, 24 (5 Suppl): 35S-38S.View ArticlePubMedGoogle Scholar
- Seeman E, Delmas PD: Bone quality--the material and structural basis of bone strength and fragility. N Engl J Med. 2006, 354: 2250-2261. 10.1056/NEJMra053077.View ArticlePubMedGoogle Scholar
- Rude RK: Magnesium deficiency: a cause of heterogeneous disease in humans. J Bone Miner Res. 1998, 13: 749-758. 10.1359/jbmr.19184.108.40.2069.View ArticlePubMedGoogle Scholar
- Rude RK, Gruber HE: Magnesium deficiency and osteoporosis: animal and human observations. J Nutr Biochem. 2004, 15: 710-716. 10.1016/j.jnutbio.2004.08.001.View ArticlePubMedGoogle Scholar
- Tucker KL, Hannan MT, Chen H, Cupples LA, Wilson PW, Kiel DP: Potassium, magnesium and fruit and vegetable intakes are associated with greater bone mineral density in elderly men and women. Am J Clin Nutr. 1999, 69: 727-736.PubMedGoogle Scholar
- Stendig-Lindberg G, Tepper R, Leichter I: Trabecular bone density in a two year controlled trial of peroral magnesium in osteoporosis. Magnes Res. 1993, 6: 155-163.PubMedGoogle Scholar
- Eisinger J, Clairet D: Effects of silicon, fluoride, etidronate and magnesium on bone mineral density: a retrospective study. Magnes Res. 1993, 6: 247-249.PubMedGoogle Scholar
- Rude RK, Olerich M: Magnesium deficiency: possible role in osteoporosis associated with gluten-sensitive enteropathy. Osteoporos Int. 1996, 6: 453-461. 10.1007/BF01629578.View ArticlePubMedGoogle Scholar
- Ikeuchi M, Ito A, Dohi Y, Ohgushi H, Shimaoka H, Yonemasu K, Tateishi T: Osteogenic differentiation of cultured rat and human bone marrow cells on the surface of zinc-releasing calcium phosphate ceramics. J Biomed Mater Res A. 2003, 67: 1115-1122.View ArticlePubMedGoogle Scholar
- Popp JR, Love BJ, Goldstein AS: Effect of soluble zinc on differentiation of osteoprogenitor cells. J Biomed Mater Res A. 2007, 81: 766-769.View ArticlePubMedPubMed CentralGoogle Scholar
- Bellia JP, Birchall JD, Roberts NB: Beer: a dietary source of silicon. Lancet. 1994, 343: 235-View ArticlePubMedGoogle Scholar
- Jugdaohsingh R: Silicon and bone health. J Nutr Health Aging. 2007, 11: 99-110.PubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2474/12/227/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.